EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin’s lymphoma via CCR7/ARHGAP18/IKBα signaling activation

Jiyu Wang, Qianshan Tao, Keke Huang, Yangyang Wang, Linhui Hu, Anwen Ren, Huiping Wang, Yang Wan, Jinlan Li, Liuying Yi, Yanjie Ruan, Zhixiang Wanyan und 3 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-009356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jiyu Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Receptors, CCR7, Cellular Senescence, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Anhui Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to existing therapies is a major cause of treatment failure in patients with refractory and relapsed B-cell non-Hodgkin’s lymphoma (r/r B-NHL). Therapy-induced senescence (TIS) is one of the most important mechanisms of drug resistance.

Methods

This study used single-cell RNA sequencing to analyze doxorubicin-induced senescent B-NHL cells. C-C chemokine receptor 7 (CCR7) expression in patients with aggressive B-NHL was assessed using immunohistochemistry and flow cytometry. Lentiviral transfection was used to target CCR7 expression in Raji and SU-DHL-2 cells. Protein localization was visualized through immunofluorescence, while western blotting and co-immunoprecipitation were used to analyze protein expression and interactions. Cell proliferation was measured with the Cell Counting Kit-8 assay, and senescent cells were detected using senescence-associated β-galactosidase staining. The stemness of cells was evaluated through colony and sphere formation assays. Transwell assays assessed cell migration and invasion. Finally, inhibitors GS143 and Y27632 were used to examine the effect of IKBα and ARHGAP/RhoA inhibition on B-NHL-TIS.

Results

Here we identified a distinct group of TIS, composed of memory B-cell population characterized by strong positive expression of CCR7, which was significantly elevated in TIS population compared with normal proliferating and autonomously senescent lymphoma cell populations. Additionally, CCR7 expression was significantly upregulated in patients with r/r B-NHL, and was an independent prognostic factor in B-NHL, with high CCR7 expression being strongly associated with poor prognosis. In vitro results indicated that CCL21 induced migration and invasion of B-NHL cells via CCR7, while blocking CCR7 reduced doxorubicin-induced migration and invasion of these cells. Furthermore, B-NHL-TIS regulated by CCR7 and exhibited enhanced phenotypic and functional stemness features, including the upregulation of stemness markers, increased colony-forming, invasive and migratory capabilities. Mechanistically, blocking CCR7 reversed the stemness characteristics of senescent B-NHL cells by inhibiting the activation of ARHGAP18/IKBα signaling.

Conclusions

Together, TIS promotes the stemness of B-NHL cells via CCR7/ARHGAP18/IKBα signaling activation and targeting CCR7/ARHGAP18 might overcome the chemoresistance of senescent B-NHL cells by inhibiting stemness acquisition and maintenance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR7Cellular SenescenceSignal TransductionHumansNF-KappaB Inhibitor alphaGTPase-Activating ProteinsNeoplastic Stem CellsCell Line, TumorDoxorubicinLymphoma, B-CellMaleFemaleCell ProliferationMiddle Aged

Stichwörter der Autor:innen

B cellChemotherapyCytokineHematologic MalignanciesStem cell

Substanzen

Receptors, CCR7CCR7 protein, humanNF-KappaB Inhibitor alphaGTPase-Activating ProteinsDoxorubicin

Autor:innen und Institutionen

  • Department of Hematology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology…
  • Department of Internal Medicine, The University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong, China.
  • Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
  • Department of Hematology, The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
  • Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Förderung

  • Natural Science Foundation of Anhui Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, J., Tao, Q., Huang, K., Wang, Y., Hu, L., Ren, A., Wang, H., Wan, Y., Li, J., Yi, L., Ruan, Y., Wanyan, Z., Wu, F., Zhai, Z., & Liu, C. (2025). Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin’s lymphoma via CCR7/ARHGAP18/IKBα signaling activation. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009356

Vancouver

Wang J, Tao Q, Huang K, Wang Y, Hu L, Ren A, et al. Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin’s lymphoma via CCR7/ARHGAP18/IKBα signaling activation. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-009356

BibTeX
@article{Wang2025,
  author = {Wang, Jiyu and Tao, Qianshan and Huang, Keke and Wang, Yangyang and Hu, Linhui and Ren, Anwen and Wang, Huiping and Wan, Yang and Li, Jinlan and Yi, Liuying and Ruan, Yanjie and Wanyan, Zhixiang and Wu, Fan and Zhai, Zhimin and Liu, Chaohong},
  title = {Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin’s lymphoma via CCR7/ARHGAP18/IKBα signaling activation},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-009356}
}
Kostenlos starten →